| Trial ID # | NCT03875820; FRAME |
| Phase | I |
| Drug Class | Signaling Pathway Inhibitors: Integrins-FAK/FAK |
| Drug Name | Defactinib |
| Alternate Drug Names | VS-6063, PF-04554878 |
| Drugs in Trial | Defactinib, Avutometinib |
| Eligible Participant | Recurrent low grade serous ovarian cancer |
| Patients Enrolled | 25, median 4 prior therapies (1-9) |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, PFS, evaluated per RECIST |
| Efficacy | RP2D [3.2 mg VS-6766 (2x/week)+200 mg defactinib (BID) q3/4 weeks] ORR: 46% (n=24) |
| Conclusion | VS-6766 (CH5127677)+defactinib shows promising clinical activity in patients with low grade serous ovarian cancer including those who have been previously treated with a MEK inhibitor |
| Reference | Coma S et al. Synergistic antitumor efficacy of the dual RAF/MEK inhibitor VS-6766 with FAK inhibition for treatment of RAS-dependent solid tumor. Cancer Res (2021) Volume 81, Issue 13 Supplement, abstract 1425 Coma S et al. Poster Banerjee S et al. Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer. Annals of Oncology (2021) 32 (suppl_5): abstract 725MO |